Tag: Mabylon
Mabylon AG Initiates Phase I Clinical Trial of Lead Compound MY006 for the Treatment of Peanut Allergy
— First study participant dosed in U.S. trial with healthy volunteers and patients with peanut allergy
— Novel, human-derived, half-life extended tri-specific monoclonal antibody to prevent allergic reactions
Mabylon AG, a leader in the high-throughput discovery, engineering, and development of human-derived antibodies for the treatment of allergies, neurodegenerative diseases, and inflammation, today announced that the first healthy volunteer has been dosed in the first-in-human clinical trial evaluating MY006, a novel tri-specific monoclonal antibody for the prophylactic treatment of peanut allergy. MY006 is based on patient-derived antibodies and designed to provide a new approach for preventing allergic reactions in individuals with peanut allergy.
Mabylon AG Receives Research Grants Totaling More Than CHF 1.3 Million for Amyotrophic Lateral Sclerosis (ALS) and Inflammasome Programs
Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has received three grants totaling more than CHF 1.3 million from Innosuisse Swiss Innovation Agency, Target ALS and the ALS Association.